The chemoprevention Phase I and II consortia must submit Letters of Intent for review and approval prior to the submission and review of the protocol.
DCP will solicit Letters of Intent from investigators who want to conduct clinical trials with specific agents.
Questions regarding the use of the templates or submission of documents may call the DCP Protocol Information Office at (240) 276-7130.
The Chemopreventive Agent Development Group supports Phase I chemoprevention trials.
All document submissions must be sent electronically to the PIO. Submissions sent elsewhere will not be accepted for review. Incomplete submissions will be returned to the Principal Investigator.
Back to top
DCP Home |
Contact DCP |
Viewing Files |
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®